Proactive inspection readiness programs that transform regulatory uncertainty into confidence, identifying gaps, strengthening systems, and preparing your team before FDA arrives.
An FDA inspection is one of the highest-stakes events a pharmaceutical or biotech company faces. Whether it's a routine surveillance inspection, a pre-approval inspection (PAI), or a for-cause investigation, your organization's readiness, or lack thereof, has direct business and regulatory consequences.
GxP Global Quality Network's inspection readiness consulting helps pharmaceutical, biotech, and life science organizations identify and address compliance vulnerabilities proactively, prepare teams to respond confidently during inspections, and build sustainable quality systems that withstand regulatory scrutiny.
Our mock inspections are structured to closely simulate actual FDA inspection methodology, including documentation requests, facility tours, personnel interviews, and record reviews. Findings are delivered in an FDA-style 483 format, giving your team a realistic experience and a clear remediation roadmap.
Quality standard: All GxP Global Quality Network engagements are led by senior-credentialed auditors with 20+ years of active GxP audit experience, regulatory currency across FDA, EMA, MHRA, and Health Canada standards, and direct accountability for every deliverable.